IBDEI0PY ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11666,1,4,0)
 ;;=4^Z52.4
 ;;^UTILITY(U,$J,358.3,11666,2)
 ;;=^5063082
 ;;^UTILITY(U,$J,358.3,11667,0)
 ;;=D47.Z1^^46^569^8
 ;;^UTILITY(U,$J,358.3,11667,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11667,1,3,0)
 ;;=3^Post-Transplant Lymphoproliferative Disorder (PTLD)
 ;;^UTILITY(U,$J,358.3,11667,1,4,0)
 ;;=4^D47.Z1
 ;;^UTILITY(U,$J,358.3,11667,2)
 ;;=^5002261
 ;;^UTILITY(U,$J,358.3,11668,0)
 ;;=N18.1^^46^570^1
 ;;^UTILITY(U,$J,358.3,11668,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11668,1,3,0)
 ;;=3^Chr Kidney Disease,Stage 1
 ;;^UTILITY(U,$J,358.3,11668,1,4,0)
 ;;=4^N18.1
 ;;^UTILITY(U,$J,358.3,11668,2)
 ;;=^5015602
 ;;^UTILITY(U,$J,358.3,11669,0)
 ;;=N18.2^^46^570^2
 ;;^UTILITY(U,$J,358.3,11669,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11669,1,3,0)
 ;;=3^Chr Kidney Disease,Stage 2
 ;;^UTILITY(U,$J,358.3,11669,1,4,0)
 ;;=4^N18.2
 ;;^UTILITY(U,$J,358.3,11669,2)
 ;;=^5015603
 ;;^UTILITY(U,$J,358.3,11670,0)
 ;;=N18.4^^46^570^6
 ;;^UTILITY(U,$J,358.3,11670,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11670,1,3,0)
 ;;=3^Chr Kidney Disease,Stage 4
 ;;^UTILITY(U,$J,358.3,11670,1,4,0)
 ;;=4^N18.4
 ;;^UTILITY(U,$J,358.3,11670,2)
 ;;=^5015605
 ;;^UTILITY(U,$J,358.3,11671,0)
 ;;=N18.5^^46^570^7
 ;;^UTILITY(U,$J,358.3,11671,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11671,1,3,0)
 ;;=3^Chr Kidney Disease,Stage 5
 ;;^UTILITY(U,$J,358.3,11671,1,4,0)
 ;;=4^N18.5
 ;;^UTILITY(U,$J,358.3,11671,2)
 ;;=^5015606
 ;;^UTILITY(U,$J,358.3,11672,0)
 ;;=N18.9^^46^570^8
 ;;^UTILITY(U,$J,358.3,11672,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11672,1,3,0)
 ;;=3^Chr Kidney Disease,Unspec
 ;;^UTILITY(U,$J,358.3,11672,1,4,0)
 ;;=4^N18.9
 ;;^UTILITY(U,$J,358.3,11672,2)
 ;;=^332812
 ;;^UTILITY(U,$J,358.3,11673,0)
 ;;=N18.6^^46^570^9
 ;;^UTILITY(U,$J,358.3,11673,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11673,1,3,0)
 ;;=3^ESRD
 ;;^UTILITY(U,$J,358.3,11673,1,4,0)
 ;;=4^N18.6
 ;;^UTILITY(U,$J,358.3,11673,2)
 ;;=^303986
 ;;^UTILITY(U,$J,358.3,11674,0)
 ;;=N19.^^46^570^10
 ;;^UTILITY(U,$J,358.3,11674,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11674,1,3,0)
 ;;=3^Kidney Failure,Unspec
 ;;^UTILITY(U,$J,358.3,11674,1,4,0)
 ;;=4^N19.
 ;;^UTILITY(U,$J,358.3,11674,2)
 ;;=^5015607
 ;;^UTILITY(U,$J,358.3,11675,0)
 ;;=N18.30^^46^570^3
 ;;^UTILITY(U,$J,358.3,11675,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11675,1,3,0)
 ;;=3^Chr Kidney Disease,Stage 3,Unspec
 ;;^UTILITY(U,$J,358.3,11675,1,4,0)
 ;;=4^N18.30
 ;;^UTILITY(U,$J,358.3,11675,2)
 ;;=^5159286
 ;;^UTILITY(U,$J,358.3,11676,0)
 ;;=N18.31^^46^570^4
 ;;^UTILITY(U,$J,358.3,11676,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11676,1,3,0)
 ;;=3^Chr Kidney Disease,Stage 3a
 ;;^UTILITY(U,$J,358.3,11676,1,4,0)
 ;;=4^N18.31
 ;;^UTILITY(U,$J,358.3,11676,2)
 ;;=^5159287
 ;;^UTILITY(U,$J,358.3,11677,0)
 ;;=N18.32^^46^570^5
 ;;^UTILITY(U,$J,358.3,11677,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11677,1,3,0)
 ;;=3^Chr Kidney Disease,Stage 3b
 ;;^UTILITY(U,$J,358.3,11677,1,4,0)
 ;;=4^N18.32
 ;;^UTILITY(U,$J,358.3,11677,2)
 ;;=^5159288
 ;;^UTILITY(U,$J,358.3,11678,0)
 ;;=N10.^^46^571^5
 ;;^UTILITY(U,$J,358.3,11678,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11678,1,3,0)
 ;;=3^Acute Tubulo-Interstitial Nephritis
 ;;^UTILITY(U,$J,358.3,11678,1,4,0)
 ;;=4^N10.
 ;;^UTILITY(U,$J,358.3,11678,2)
 ;;=^5015570
 ;;^UTILITY(U,$J,358.3,11679,0)
 ;;=N17.1^^46^571^1
 ;;^UTILITY(U,$J,358.3,11679,1,0)
 ;;=^358.31IA^4^2
